DC ChemicalsChemicals for Life Science
sales@dcchemicals.com

DC60782 · Updated 24 October 2026

Lipid A4B4-S3
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

Literature-reported formulation composition

Componentmol%Role
A4B4-S350Ionizable lipid
DSPC10Helper phospholipid
Cholesterol38.5Sterol
C14-PEG20001.5PEG lipid
Reported total100Source values retained
Formulation calculator unavailable. The 4 reported lipid components total 100 mol%. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Not reported in the cited article
mRNA aqueous phase used 10 mM citrate buffer at pH 4.0; PBS was used for dialysis.
Luciferase mRNA, Cre mRNA and hEPO mRNA
Intramuscular and retro-orbital intravenous mouse administration as specified per assay.
Luciferase IM comparison 0.05 mg/kg; Cre reporter 0.5 mg/kg on days 0 and 3; hEPO retro-orbital IV 0.25 mg/kg, with repeat-dose schedule every 7 days for five doses.
Mice, including Ai9 Cre-reporter animals and liver gene-expression/protein-replacement models.
Ethanolic lipid phase and mRNA aqueous phase were mixed with a T-junction syringe-pump setup. The post-mixing formulation was dialyzed against 1× PBS in a 10,000 MWCO cassette at 4 °C for 12 h.

Literature-reported performance for the cited formulation

Literature-reportedA4B4-S3 outperformed H2A4B4 and A4B4-S4 in the reported comparison.0.05 mg/kg luciferase mRNA; n=3 · H2A4B4 and A4B4-S4PMC article, Fig. 3I
Literature-reportedCD45−/CD31− nonhematopoietic/nonendothelial population editing was 56% for A4B4-S3 versus 48% for SM-102; overall immune-cell editing was 34% versus 28%.Ai9 mice; 0.5 mg/kg Cre mRNA on days 0 and 3; liver readout day 5 · SM-102PMC article, Fig. 3J and text
Literature-reportedA4B4-S3 produced the highest reported hEPO peak among the compared formulations and maintained repeat-dose peaks in the five-dose schedule.0.25 mg/kg hEPO mRNA retro-orbital IV; peak at 6 h; every 7 days ×5 · A4B4-S4 and SM-102PMC article, hEPO section and Fig. 3L-M
Literature-reportedThe article reports no significant ALT/AST or H&E abnormalities in the tested repeat-dose mouse study.Five weekly hEPO mRNA doses · Comparator LNP groupsPMC article safety narrative; SI Fig. S14 is referenced but not accessed
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetXu Y, Gong F, Golubovic A, et al. Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery. Proc Natl Acad Sci U S A. 2025;122(5):e2409572122.
Claims apply to the cited A4B4-S3 LNP formulation and mouse assays, not to the neat lipid alone.

PMC full text · DOI